Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

Part of paid clinical trials in Tucson, Arizona.

Sponsor
University of Arizona
Study ID
NCT04820179
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib + Atezolizumab — DRUG
    All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).

Study Details

Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease. Combination treatment with cabozantinib and atezolizumab, has demonstrated safety for the treatment of other cancers and has shown promise in preclinical studies utilizing patient derived pancreas organoids. In this study, patients with refractory, metastatic pancreatic cancer will receive combination cabozantinib + atezolizumab and the efficacy of this treatment will be assessed through overall response rate (ORR), disease control rate (DCR), median overall survival (mOS), and median progression free survival (mPFS). Safety and tolerability of combination cabozantinib plus atezolizumab in metastatic pancreatic cancer patients will also be assessed and immune profiling pre- and post-treatment will be explored.

Key Dates

Start date
Oct 12, 2021
Status verified
Mar 2026
Primary completion
Feb 20, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib 40mg + Atezolizumab 1200mg
    Cabozantinib 40 mg, tablets, oral administration, once daily, continuously. Atezolizumab 1200 mg, administered intravenously, on Day 1 of every 21 day cycle.

Primary Outcome Measure

Overall Response Rate or Stable Disease [ Time Frame: Participants will be evaluated for response every 3 cycles (each cycle is 21 days) thereafter until disease progression or death from any cause, whichever occurs first (an average of 6 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Arizona Cancer CenterTucsonArizona85724-

Find similar trials in Tucson, AZ

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
University of Arizona Cancer Center· Tucson, AZ

Related Studies